The Roadmap of Colorectal Cancer Screening

Ferlizza, Enea; Solmi, Rossella; Sgarzi, Michela; Ricciardiello, Luigi; Lauriola, Mattia

doi:10.3390/cancers13051101

Cited by 41 publications

(22 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FOBT and FIT have low sensitivity in pre-neoplastic lesion detection and a high false positive detection rate. Furthermore, colonoscopy is an invasive procedure with poor compliance among those eligible for CRC screening [ 2 , 3 ]. Therefore, there is a need for new reliable biomarkers, which can predict risks of early recurrence and metastasis in CRC patients, biomarkers that could be easily incorporated into the routine diagnostic workup [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis

et al. 2022

View full text Add to dashboard Cite

There is growing interest in single nucleotide polymorphisms (SNPs) in the genes of microRNAs (miRNAs), which could be associated with susceptibility to colorectal cancer (CRC) and therefore for prognosis of the disease and/or treatment response. Moreover, these miRNAs-SNPs could serve as new, low-invasive biomarkers for early detection of CRC. In the present article, we performed a thorough review of different SNPs, which were investigated for a correlation with the CRC risk, prognosis, and treatment response. We also analyzed the results from different meta-analyses and the possible reasons for reported contradictory findings, especially when different research groups investigated the same SNP in a gene for a particular miRNA. This illustrates the need for more case-control studies involving participants with different ethnic backgrounds. According to our review, three miRNAs-SNPs—miR-146a rs2910164, miR-27a rs895819 and miR-608 rs4919510—appear as promising prognostic, diagnostic and predictive biomarkers for CRC, respectively.

show abstract

Section: Introductionmentioning

confidence: 99%

Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It, therefore, may remain a primary screening procedure for CRC. However, other research directions pursue raising sensitivity and specificity of currently available alternative screening procedures, such as the imagistic analysis [ 8 ], epigenetic faecal biomarkers [ 9 ], urine, and exhaled breath or blood-based biomarkers [ 10 ]. In Europe, Colon Capsule Endoscopy is currently considered acceptable as a screening method regarding specificity and sensitivity.…”

Section: Introductionmentioning

confidence: 99%

State-of-the-Art Review on Immersive Virtual Reality Interventions for Colonoscopy-Induced Anxiety and Pain

Găină

Szalontay

Ştefănescu

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Colonoscopy related fear impairs the current gold standard screening of colorectal cancer. Compared to other minimally invasive procedures for cancer screening, colonoscopy-induced anxiety exceeds the procedure through bowel preparation. Immersive virtual reality’s (iVR) role in alleviating the complex stress–pain relationship encountered during medical procedures is directly proportional to the rising affordability of state-of-the-art Head-Mounted-Displays (HMDs). Objective: to assess the effect of iVR on patients’ colonoscopy-induced anxiety and pain. Materials and methods: A systematic search was conducted in PubMed, Cochrane Central Register of Controlled Trials, Web of Science, Embase and Scopus databases up to January 2022. Clinical trials evaluating anxiety as an outcome were included without language restriction. Results: Four clinical trials were included: three on the patients’ intraprocedural anxiety and one on patient education. Intraprocedural iVR interventions for colonoscopy-induced anxiety and pain revealed a similar effect as conventional sedation, while a statistically significant reduction was reported for non-sedated patients. iVR patient education improved the quality of bowel preparation and reduced patient anxiety before colonoscopy. Conclusions: The current research highlights the need to use high-end HMDs and appropriate interactive iVR software content for colonoscopy-induced anxiety. Methodological frameworks regarding the eligibility of participants, double-blinding and randomization of iVR studies can facilitate the development of iVR implementation for anxiety and pain management.

show abstract

“…27,28 The favourable trends in colorectal cancer are largely attributable to progress in early diagnosis, screening, treatment and management of the disease. 29,30 The less favourable rates and trends in Poland likely reflect lesser and later adoption of these protocols there, and probably in other countries of central and eastern Europe. The consistently lower rates and more favourable trends in women from cohorts born after the 1930s suggest a possible favourable effect of female hormones.…”

Section: Annals Of Oncologymentioning

confidence: 99%

European cancer mortality predictions for the year 2022 with focus on ovarian cancer

et al. 2022

View full text Add to dashboard Cite

Background: Cancer mortality rates, though not absolute numbers of deaths, have been decreasing over the last three decades in Europe. Materials and methods: We estimated projections and the number of avoided deaths for total cancer mortality and 10 major cancer sites, between 1989 and 2022, for the European Union (EU), the UK, France, Germany, Italy, Poland and Spain using cancer death certification and population data since 1970 from the World Health Organization and Eurostat. Results: In the EU, we predict 1 269 200 cancer deaths in 2022; corresponding age-standardized rates (world) fall 6% to 126.9 deaths/100 000 in men and 4% to 80.2/100 000 women since 2017. Male lung cancer is expected to fall 10% reaching 30.9/100 000. The rise in female lung cancer mortality slowed (þ2% to 13.8/100 000). We estimated 369 000 (23%) avoided deaths in 2022 alone and a total of 5 394 000 (12%) deaths since the peak rate in 1988. Stomach, colorectal, breast and prostate cancers showed substantial declines, between 5% and 16% over the past 5 years. Pancreatic cancer remained stable in men (8.1/100 000) and rose 3% in women (5.9/100 000), becoming the third cause of cancer mortality in the EU (87 300 deaths), overtaking breast cancer (86 300 deaths). The fall in uterine cancers slowed down (À4%) to 4.7/100 000. Bladder cancer fell 9% in men, but was stable in women. Leukaemias fell more than 10%. Ovarian cancer mortality declined over the past decade in all considered countries. EU predicted rates were 4.3/100 000 (À13%) all ages, 1.2/100 000 (À26%) at 20-49, 15.3/100 000 (À11%) at 50-69 and 32.3/100 000 (À11%) at 70-79 years. Conclusions: We predicted additional declines in cancer mortality rates for 2022. The slowdown in female lung cancer mortality reflects some levelling of smoking in women. Favourable ovarian cancer trends are likely to continue and are largely attributable to the spreading oral contraceptive use and some impact of improved diagnosis and management.

show abstract

The Roadmap of Colorectal Cancer Screening

Cited by 41 publications

References 138 publications

Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis

Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis

State-of-the-Art Review on Immersive Virtual Reality Interventions for Colonoscopy-Induced Anxiety and Pain

European cancer mortality predictions for the year 2022 with focus on ovarian cancer

Contact Info

Product

Resources

About